Aromatase (CYP19)

Subscribe to Selected New Research on Aromatase

2120 relevant articles (124 outcomes, 424 trials/studies) found for this Bio-Agent

Description: An enzyme that catalyzes the desaturation (aromatization) of the ring A of C19 androgens and converts them to C18 estrogens. In this process, the 19-methyl is removed. This enzyme is membrane-bound, located in the endoplasmic reticulum of estrogen-producing cells of ovaries, placenta, testes, adipose, and brain tissues. Aromatase is encoded by the CYP19 gene, and functions in complex with NADPH-FERRIHEMOPROTEIN REDUCTASE in the cytochrome P-450 system.

Also Known As:

CYP19; Androstenedione Aromatase; CYP 19; CYP19 Protein; Cytochrome P450 19; Estrogen Synthase; Estrogen Synthetase; P450AROM; Aromatase, Androstenedione; Cytochrome P 450 CYP19; Protein, CYP19; Cytochrome P-450 CYP19; Cytochrome P-450(AROM)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Bulun, Serdar E: 10 articles (03/2008 - 10/2002)
2.	Brueggemeier, Robert W: 9 articles (03/2008 - 09/2003)
3.	Simpson, Evan R: 9 articles (01/2008 - 01/2002)
4.	Sasano, Hironobu: 8 articles (07/2008 - 05/2002)
5.	Suzuki, Takashi: 7 articles (07/2008 - 05/2002)
6.	Chen, Shiuan: 7 articles (06/2008 - 06/2002)
7.	Lin, Zhihong: 7 articles (03/2008 - 05/2005)
8.	Shozu, Makio: 7 articles (08/2006 - 06/2002)
9.	Miki, Yasuhiro: 6 articles (07/2008 - 01/2005)
10.	Inoue, Masaki: 6 articles (08/2006 - 06/2002)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 02/01/2009 - "Elucidation of the structure-function relationship of aromatase has been of significant interest since its inhibitors have shown great promise in fighting breast cancer. " 05/01/2009 - "Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial." 05/15/2009 - "Here, we tested the antitumor efficacy of combined Src and aromatase inhibition for ER-positive breast cancer. " 02/25/2000 - "Anti-aromatase, antiestrogenic or antiproliferative actions of these compounds have been postulated and related to the observation that there is a reduced incidence of breast cancer associated with diet. " 09/01/2009 - "METHODS: EFECT is a randomised, double-blind, multicentre, Phase III trial in postmenopausal women with advanced breast cancer progressing or recurring after prior non-steroidal aromatase inhibitor therapy. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 08/01/2005 - "Sensitivity analyses suggest that sequential treatment strategies optimized 10-year disease-free and distant disease-free survival independent of the degree of the beneficial carryover effect after aromatase inhibitor therapy or the ratio of local to distant tumor recurrence. " 10/01/1993 - "Aromatase activity was significantly greater in PR-positive tumors than in PR-negative tumors (p < 0.002). " 11/15/2009 - "Collectively, results from this study provide data to support that HSP90 inhibitors may be an effective therapy to treat aromatase inhibitor-resistant breast cancers and that improved efficacy can be achieved by combined use of a HSP90 inhibitor and an AKT inhibitor." 01/01/2008 - " is a unique case as it illustrates how treatment with an aromatase inhibitor leading to cancer regression can result in an improvement in the paraneoplastic symptoms." 03/01/1996 - "These results suggest that, similar to our previous findings in the breast bearing a tumor, adipose tissue aromatase expression in the disease-free breast is determined by the local ratio of fibroblasts to adipocytes." Order ALL the reference details at left...
3.	Endometriosis (Adenomyosis) 11/01/2008 - "OBJECTIVE: To present a case demonstrating lack of efficacy of an aromatase inhibitor in treating ureteral endometriosis. " 01/01/2007 - "This study investigated whether polymorphisms of the CYP19 gene are associated with the risk of advanced endometriosis in Korean women. " 08/01/2006 - "The aim of the present study was to measure the in vitro aromatase activity in granulosa cells of women with endometriosis submitted to assisted reproduction techniques. " 08/01/2002 - "For ovarian endometrioma, previous studies have been conducted ex vivo using cells obtained from endometrioma and have demonstrated that steroidogenic factor-1 is involved in the expression of aromatase. " 01/01/1996 - "The present study was conducted to determine the presence or absence of aromatase expression in peritoneal endometriotic implants and in the eutopic endometrium of women with endometriosis. " Order ALL the reference details at left...
4.	Carcinoma (Carcinomatosis) 07/01/2008 - "This review summarizes the results of recent studies on the expression and regulation of aromatase in breast carcinoma tissues, and discusses the potential biological and/or clinical significance of aromatase. " 01/01/2008 - "Therefore, in this review, we summarize the results of recent studies on aromatase in breast carcinoma, and we discuss its biological and/or clinical significance. " 01/01/2008 - "In the present study, we examined aromatase expression in gastric carcinoma. " 04/15/2007 - "We further examined an interaction between stromal cells isolated from human breast carcinoma tissues and breast carcinoma cell lines using a coculture system to study the biological characteristic of aromatase expression in carcinoma cells. " 03/15/2007 - "Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials." Order ALL the reference details at left...
5.	Leiomyoma (Uterine Fibroids) 01/01/2008 - "The aim of this study was to investigate CYP17A1, CYP19, and androgen (AR) polymorphisms, their relative risks for uterine leiomyomas and possible associations with clinical parameters. " 05/01/2009 - "High aromatase expression in uterine leiomyoma tissues of African-American women." 01/01/2009 - "OBJECTIVE: To assess the effect of the aromatase inhibitor on patients with leiomyoma in the reproductive stage regarding reduction of uterine volume and control of symptoms. " 01/01/2009 - "Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients." 03/01/2008 - "Definition of this mechanism further may assist in designing inhibitors of aromatase specific for leiomyoma tissue." Order ALL the reference details at left...

Related Drugs and Biologics

1.	anastrozole (Arimidex)
2.	letrozole (Femara)
3.	Tamoxifen
4.	Estrogens (Estrogen)
5.	Hormones
6.	exemestane (Aromasin)
7.	Estrogen Receptor Modulators (Antiestrogen)
8.	Aromatase Inhibitors
9.	Aromatase (CYP19)
10.	formestane

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Drug Therapy (Chemotherapy)
3.	Chemoprevention
4.	Oral Administration
5.	Ovariectomy (Oophorectomy)

Best Treatments:
Research Summary Report
on Breast Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3868 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>